According to recent research,eIF3d is overexpressed in a number of cancerous tumors,such as melanoma,3 prostate cancer,4 and colon cancer.5 In a number of cancer types, eIF3d has also been identifiedas a possible therapeutic target.2,3,6 Recent data suggest that dysregulated eIF3d expression plays a significant role in cancer and various geneticdisorders, highlighting the urgent need for innovative detection strategies.This underscores the growing demand for advances in cancer biomarkerscreening and detection. This evidence concerns the gene EIF3D and prostate carcinoma.